193 related articles for article (PubMed ID: 30114962)
1. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.
Loessner D; Goettig P; Preis S; Felber J; Bronger H; Clements JA; Dorn J; Magdolen V
Expert Opin Ther Targets; 2018 Sep; 22(9):745-763. PubMed ID: 30114962
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
[TBL] [Abstract][Full Text] [Related]
4. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
Tamir A; Jag U; Sarojini S; Schindewolf C; Tanaka T; Gharbaran R; Patel H; Sood A; Hu W; Patwa R; Blake P; Chirina P; Oh Jeong J; Lim H; Goy A; Pecora A; Suh KS
J Ovarian Res; 2014 Dec; 7():109. PubMed ID: 25477184
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer.
Riedel M; Bronger H; Magdolen V; Dreyer T
Expert Rev Mol Diagn; 2021 Jun; 21(6):535-545. PubMed ID: 33947310
[No Abstract] [Full Text] [Related]
6. Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Seidl C; Diamandis EP; Kiechle M; Drecoll E; Kotzsch M; Magdolen V; Dorn J
BMC Cancer; 2019 Jul; 19(1):696. PubMed ID: 31307411
[TBL] [Abstract][Full Text] [Related]
7. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.
Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA
Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
Wang P; Magdolen V; Seidl C; Dorn J; Drecoll E; Kotzsch M; Yang F; Schmitt M; Schilling O; Rockstroh A; Clements JA; Loessner D
Br J Cancer; 2018 Oct; 119(7):1-9. PubMed ID: 30287916
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein-related peptidases in lung diseases.
Lenga Ma Bonda W; Iochmann S; Magnen M; Courty Y; Reverdiau P
Biol Chem; 2018 Sep; 399(9):959-971. PubMed ID: 29604204
[TBL] [Abstract][Full Text] [Related]
10. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
[TBL] [Abstract][Full Text] [Related]
11. Metastasis of ovarian cancer is mediated by kallikrein related peptidases.
Dong Y; Loessner D; Irving-Rodgers H; Obermair A; Nicklin JL; Clements JA
Clin Exp Metastasis; 2014 Jan; 31(1):135-47. PubMed ID: 24043563
[TBL] [Abstract][Full Text] [Related]
12. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
13. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
14. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
[TBL] [Abstract][Full Text] [Related]
15. Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.
Pépin D; Shao ZQ; Huppé G; Wakefield A; Chu CW; Sharif Z; Vanderhyden BC
PLoS One; 2011; 6(11):e26075. PubMed ID: 22102857
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy.
Silva LM; Clements JA
Expert Rev Proteomics; 2017 Dec; 14(12):1119-1130. PubMed ID: 29025353
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein-related peptidases (KLKs) and the hallmarks of cancer.
Filippou PS; Karagiannis GS; Musrap N; Diamandis EP
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):277-91. PubMed ID: 26886390
[TBL] [Abstract][Full Text] [Related]
19. Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression.
Bayani J; Kuzmanov U; Saraon P; Fung WA; Soosaipillai A; Squire JA; Diamandis EP
Clin Chem; 2013 Jan; 59(1):296-305. PubMed ID: 23136250
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression of Kallikreins in Breast Cancer Cell Lines.
Watrowski R; Castillo-Tong DC; Obermayr E; Zeillinger R
Anticancer Res; 2020 May; 40(5):2487-2495. PubMed ID: 32366393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
